Who is sponsoring NCT03152292?

NCT03152292 is sponsored by ACADIA Pharmaceuticals Inc..

What drugs are being tested in NCT03152292?

Interventions in NCT03152292: Real-world, non-interventional.

What condition does NCT03152292 study?

NCT03152292 studies Parkinson Disease Psychosis.

Is NCT03152292 still recruiting?

NCT03152292 is currently terminated. Last updated 6 August 2021.

Last reviewed 2021-08-06 · How we verify

NCT03152292

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Terminated Last updated 6 August 2021

What this trial tests

trial testing Real-world, non-interventional in Parkinson Disease Psychosis in 764 participants. Terminated before completion.

Timeline

30 March 2017

Primary endpoint
8 March 2021

8 March 2021

Quick facts

Lead sponsor	ACADIA Pharmaceuticals Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	764
Start date	30 March 2017
Primary completion	8 March 2021
Estimated completion	8 March 2021
Sites	69 locations across United States

Drugs / interventions tested

Real-world, non-interventional

Conditions studied

Parkinson Disease Psychosis — all drugs for Parkinson Disease Psychosis →

Sponsor

ACADIA Pharmaceuticals Inc. — full company profile →

Who can join

18 and older, any sex, with Parkinson Disease Psychosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
Heim B, Peball M, Krismer F, Djamshidian A, et al · · 2023

Verify or expand the search:

Other ACADIA Pharmaceuticals Inc. trials

Trials by the same sponsor.

NCT05555615 — Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder · Phase 2, PHASE3 · terminated
NCT05523895 — Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder · Phase 2, PHASE3 · completed
NCT04988867 — An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome · Phase 2, PHASE3 · terminated
NCT05008835 — Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee · Phase 2 · terminated
NCT04855240 — Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03152292 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ACADIA Pharmaceuticals Inc.
Last refreshed: 6 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03152292.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing